Skin Autofluorescence Is Not Increased in Patients with Systemic Sclerosis PDF Print E-mail
Thursday, 01 March 2012 15:52
M. E. Hettema, H. Bootsma, R. Graaff, R. de Vries, C. G. M. Kallenberg, and A. J. Smit
Received 24 May 2011; Accepted 8 August 2011

Vascular involvement is a key factor in major manifestations of systemic sclerosis (SSc), such as Raynaud’s phenomenon (RP), myocardial dysfunction, pulmonary hypertension, and renal involvement. Microvascular involvement, in which endothelial injury is present, is the main characteristic of SSc. Oxidative stress has been suggested as a major player in the process of endothelial dysfunction found in SSc. Endothelial damage may be induced by oxygen free radicals and reactive nitrogen species, generated locally by the inflammatory process and by periods of tissue ischemia followed by postischaemic reperfusion. This socalled ischaemic-reperfusion injury can be seen in RP. Increased levels of antibodies against oxidised low-density lipoproteins (LDL) and increased serum levels of 8-isoprostane, being markers of oxidative stress, have, indeed, been observed in SSc.

Oxidative or carbonyl stress, leading to formation of so-called reactive carbonyl compounds, is an important source for the generation of so-called advanced glycation endproducts (AGEs). AGE generation as a result of oxidative stress has also been found in inflammatory diseases, such as rheumatoid arthritis and SLE.

Tissue autofluorescence (AF) is a marker of the accumulation of AGEs, validated in different patient groups and healthy controls. Therefore, we assessed AGE accumulation in patients with SSc and hypothesized that AGE accumulation is increased in patients with SSc compared to healthy controls based on the presence of oxidative stress and endothelial dysfunction in SSc. We related AGE accumulation to the presence of disease-related and traditional cardiovascular risk factors.

Continue reading the full article, by downloading it from the link provided below.

 
More articles :

» Biomarker Shows Promise In Scleroderma

A biomarker that can be used to screen patients for has shown promise in a proof of concept study. Researchers from St Vincent’s in Melbourne found (ADMA) levels had an acceptable high specificity and sensitivity for detecting the complication,...

» Mixed Connective Tissue Disease May Represent Subset of Systemic Scleroderma

Many patients with (MCTD) may represent a subset of Systemic , rather than a disease involving overlapping connective tissue disorders as is commonly believed, or a subset of Lupus as some have suggested over the years, Dr. Virginia Steen said at...

» Scleroderma Research Foundation To Host Patient Webinar Series

The announced the first in a series of free informational Webinars for people living with and others directly or indirectly affected by the disease. The first Webinar will highlight new clinical trials and results from recent studies.The 2011/2012...

» Rare Disease Research Teams Receive Over $17m In Funding

(CIHR) has formed 9 new research teams that will focus on rare diseases. Funding from the CIHR will total $15.4 million over five years, primarily through the Institute of Genetics and the Institute of Nutrition, Metabolism, and Diabetes, while...

» A Call For Better Monitoring and Treatment Of Scleroderma Patients

The New Zealand Scleroderma Group is calling for the introduction of a monitoring and treatment programme for New Zealanders with scleroderma to mark World Scleroderma Day on June 29.Scleroderma is an autoimmune connective tissue disease that can...

» Calcinosis

Background:The Foundation has recently received some feedback from some members of the public asking for more information regarding the condition known as Calcinosis. As part of our efforts we sought to provide a brief, yet informative insight into...